Navigation Links
Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity
Date:12/16/2008

(MilkPEP) in Washington, D.C., which is funded by the nation's milk processors, who are committed to increasing fluid milk consumption. Lowe New York is the creative agency for the National Milk Mustache "got milk?(R)" Campaign.

About Usher

At 30 years old, Usher Raymond has achieved global superstardom that's taken him from the top of the Billboard charts, to the Broadway stage, to the boardroom. After selling 35 million albums worldwide and winning countless awards and accolades, including five GRAMMY(R) awards, Usher truly has reached iconic status. got noise? is a natural extension of his love and empowerment of teens. As the visionary leader behind his own "New Look Foundation," Usher empowers youth to jumpstart careers in the entertainment and sports industries.

About Usher's New Look Foundation

Usher's New Look was established to empower youth from underserved communities by giving them the skills necessary to enter careers in the sports and entertainment industry with the intent of increasing their economic status and decreasing at-risk behavior. The foundation accomplishes this through exposure, experience and employment opportunities. For more information about Usher's New Look, visit http://www.ushersnewlook.org.


'/>"/>
SOURCE Milk Processor Education Program
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bone Crusher, the King of VH1s Celebrity Fit Club With the Record of Biggest Individual Weight Loss, Releases Fitness DVD!
2. Unique Simulation Training Course Ushers in New Era of Stroke Intervention
3. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
4. Figure Skater Peggy Fleming Teams with HealthSaver: Raise Healthy Children Through Active Parenting
5. Teamsters Applaud Passage of Legislation to Protect Workers From Diacetyl Exposure
6. Creating Effective Cross-Functional Teams for Pharmaceutical Commercialization Success
7. TeamStaff Receives A Letter of Reprimand From Nasdaq; No Further Action Contemplated
8. Natural Disaster Rescue Teams at Public Health Facilities Across the Country Learn from Katrina Failures
9. Figure Skater Peggy Fleming Teams With HealthSaver: Cook Your Way to a Healthy Diet
10. Riverside Partners Teams with Management to Acquire GEMCITY Engineering & Manufacturing
11. VIDEO from Medialink and General Mills: Ellen DeGeneres Teams Up with Pink for the Cure
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 1NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 2NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 3Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 1Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 2Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 3Gene Therapy Brings New Muscle to Monkeys 61251 1
Other Medicine Technology:Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6